.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AE03_Cilansetron.Cilansetron .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AE03_Cilansetron.Cilansetron| name: | Cilansetron | |
| ATC code: | A03AE03 | route: | oral |
| compartments: | 2 | |
| dosage: | 2 | mg |
| volume of distribution: | 130 | L |
| clearance: | 21 | L/h |
| other parameters in model implementation | ||
Cilansetron is a selective serotonin 5-HT3 receptor antagonist that was developed for the treatment of irritable bowel syndrome (IBS), particularly for diarrhea-predominant IBS. The drug showed promise in clinical trials, especially for male patients, but it was never approved for widespread use and is not marketed today.
Estimated pharmacokinetic parameters for a typical healthy adult based on class similarity with other 5-HT3 antagonists (such as ondansetron). No direct published PK study found for cilansetron.